(273 days)
The Diagnostic Hybrids D3 DFA Herpes Simplex Virus Identification Kit is intended for use in the qualitative detection of human herpes simplex virus (HSV) in cell cultures by immunofluorescence using fluoresceinated monoclonal antibodies (MAbs). Negative results do not preclude an infection and should not be used as the sole basis for diagnosis, treatment or other management decisions.
Performance using direct specimen testing has not been evaluated.
The Diagnostic Hybrids D3 DFA Herpes Simplex Virus Identification Kit includes a DFA Reagent that contains a blend of four fluorescein-labeled murine monoclonal antibodies (MAbs), two directed against HSV type 1 (HSV-1) and two against HSV type 2 (HSV-2). The HSV-1 MAbs were developed using HSV-1(f) cell lysate as immunogen -- one has been determined to be directed against HSV-1 glycoprotein C1, the antigen to the other is undetermined. The HSV-2 MAbs were developed using a HSV-2 recombinant glycoprotein G immunogen.
The kit includes the following components:
• HSV DFA Reagent - A blend of fluorescein labeled murine monoclonal antibodies directed against antigens produced in HSV-infected cell culture. The buffered, stabilized, aqueous solution contains Evan's Blue as a counter-stain and 0.1% sodium azide as preservative.
• HSV Antigen Control Slides - Individually packaged control slides containing wells with cell culture derived positive and negative control cells. Each HSV positive well is identified. The negative wells contain uninfected cells. Each slide is intended to be stained only one time.
• PBS Concentrate - A 40X concentrate consisting of 4% sodium azide in phosphate buffered saline (after dilution to 1X in water, the concentration of sodium azide in the solution is 0.1%).
• Mounting Fluid - an aqueous, buffered, stabilized solution of glycerol and 0.1% sodium azide.
The cells to be tested, on a slide prepared from a tube culture or on a monolayer of cells cultured in a multi-well plate or a coverslip in a shell vial, are fixed in acetone. The HSV DFA Reagent is added to the cells to detect the presence of HSV specific viral antigens. After incubating for 15 to 30 minutes at 35° to 37°C, the stained cells are washed with the supplied Phosphate Buffered Saline (PBS). To prepare the slide for examination, a drop of the supplied Mounting Medium is added to the stained cells and a coverslip is placed on the slide. To prepare the centrifuge enhanced cell cultures for examination, a drop of Mounting Fluid is placed on a clean microscope slide. The coverslip is removed from the shell vial and placed on to the Mounting Fluid.
For multi-well plates, monolayers are fixed with an 80% aqueous acetone solution. The HSV DFA Reagent is added to the cells to detect the presence of any HSV specific viral antigens. After incubating for 15 to 30 minutes at 35° to 37°C, the stained cells are washed with the supplied Phosphate Buffered Saline (PBS). Mounting Fluid is added to each well to cover the monolayers.
The slides or wells are examined using a fluorescence microscope equipped with the correct filter combination for FITC at a magnification of 100-400X. Virus infected cells will be stained with bright apple-green fluorescence while uninfected cells will contain no apple-green fluorescence but will fluoresce red by the Evan's Blue counterstain' which is included in the HSV DFA Reagent.
If no fluorescent cells are found, report result as, "No herpes simplex virus detected". If fluorescent cells are found, report result as, "Herpes simplex virus isolated by cell culture."
Included in the kit are HSV Antigen Control Slides. A Control Slide is intended to function as an indicator that the kit reagents are working properly in the test. [The slides are prepared with wells of HSV infected cells and uninfected cells.] Positive and negative controls must demonstrate appropriate staining characteristics for specimen results to be valid. Controls may also aid in the interpretation of test results.
It is recommended that cell culture positive (infected with known HSV isolate) and negative (uninfected cells) controls be run with each assay to provide a means to ensure adequate performance of the cell culture system used. If control cultures fail to perform correctly, results are considered invalid.
Here's a breakdown of the acceptance criteria and the study details for the D3 HERPES SIMPLEX VIRUS IDENTIFICATION KIT, based on the provided 510(k) summary:
1. Table of Acceptance Criteria and Reported Device Performance:
| Acceptance Criteria (Implicit for equivalence) | Reported Device Performance (Clinical Performance) |
|---|---|
| High Positive Percent Agreement (PPA) with comparison device | PPA: 99.5% (95% CI: 97.3% - 100%) |
| High Negative Percent Agreement (NPA) with comparison device | NPA: 99.7% (95% CI: 98.3% - 100%) |
| No cross-reactivity with common microorganisms (viruses, bacteria, yeast, protozoans, and cell lines) | No cross-reactivity observed for 59 viral strains, 17 host cell types, 27 bacterial cultures, 1 yeast, and 1 protozoan culture. (Except for Staphylococcus aureus, which produces small, distinguishable fluorescent points due to Protein A binding, not viral antigen binding). |
| Staining patterns similar to predicate devices | Staining patterns of conjugated monoclonal antibodies on HSV infected cells were similar to those of the predicate devices. |
| Reactivity with ATCC reference HSV-1 and HSV-2 strains | All tested ATCC reference HSV-1 and HSV-2 strains reacted with the reagent. |
2. Sample Size Used for the Test Set and Data Provenance:
- Sample Size: 530 specimens were initially collected. After excluding 3 specimens due to bacterial contamination, 527 specimens were used for analysis.
- Data Provenance: The data was collected from four different laboratories as part of a clinical study. The information does not specify the country of origin, but the company address is in Athens, Ohio, USA, suggesting the study likely took place in the US. The study appears to be prospective as it involved comparing the D3 DFA HSV Kit performance to comparison tests using these specimens. The specimens were a combination of fresh (250) and frozen (280).
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts:
The document does not explicitly state the number of experts used to establish the ground truth or their specific qualifications. However, it indicates that the comparison was made against "comparison tests" which are legally marketed devices (predicates: Bartels® Herpes Simplex Virus Fluorescent Monoclonal Antibody Test, Pathodx® Herpes Typing Kit, MicroTrak® HSV 1/HSV 2 Culture Identification and Typing Test). The "comparison device" results were used as the reference against which the subject device was evaluated. It is implied that these comparison tests' results, and their interpretation, constitute the ground truth.
4. Adjudication Method for the Test Set:
The document does not explicitly describe an adjudication method for discrepancies between the subject device and the comparison device. The agreement percentages are calculated directly based on the reported positive and negative results from both the subject and comparison devices.
5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study:
A Multi-Reader Multi-Case (MRMC) comparative effectiveness study was NOT done in the context of human readers improving with AI vs. without AI assistance. This device is a diagnostic kit (reagent and controls) for laboratory use, specifically for immunofluorescence detection of HSV in cell cultures, not an AI-powered diagnostic tool for human interpretation.
6. Standalone (Algorithm Only) Performance:
Not applicable as this is a laboratory diagnostic kit, not an algorithm. The kit relies on a trained laboratory professional to perform the staining and interpret the results under a fluorescence microscope.
7. Type of Ground Truth Used:
The ground truth was established by comparison to legally marketed predicate devices (comparison tests). The "comparison device" results from cell cultures are considered the reference standard for the clinical performance evaluation. The clinical performance section states, "Clinical studies have been conducted at four different laboratories where they compared the D3 DFA HSV Kit performance to that of comparison tests..."
8. Sample Size for the Training Set:
The document does not mention a training set in the context of machine learning or AI. This is a traditional laboratory diagnostic kit, not an AI-driven product. The "training" for such a kit would involve laboratory personnel learning to use the kit according to its instructions.
However, if we interpret "training set" as the data used for internal development and optimization of the reagent, the analytical specificity and reactivity tests provide some insight into the range of organisms and conditions tested during development. The cross-reactivity panel included 59 viral strains, 17 host cell types, 27 bacterial cultures, 1 yeast, and 1 protozoan culture. The analytical specificity included ATCC reference HSV-1 and HSV-2 strains.
9. How the Ground Truth for the Training Set Was Established:
As mentioned, there isn't a "training set" in the AI sense. For the analytical studies (specificity, cross-reactivity), the ground truth was established by:
- Known (ATCC reference) HSV-1 and HSV-2 strains: These were confirmed positive for HSV.
- Known uninfected cell cultures: Used as negative controls and for testing specificity against various cell lines.
- Known cultures of other microorganisms (viruses, bacteria, yeast, protozoans): These were confirmed non-HSV organisms to test for cross-reactivity. The concentration of these organisms was also tested at high titers to challenge the specificity.
- Commercially available slides: Some cross-reactivity testing used commercially prepared slides for certain organisms, implying the manufacturer of those slides established their content.
{0}------------------------------------------------
DIAGNOSTIC HYBRIDS, INC 350 West State Street Athens, OHIO 45701
Image /page/0/Picture/1 description: The image shows the logo for Diagnostic Hybrids, which includes an image of a person with their arms raised and a DNA strand. The text "Integrating Science and Humanity" is below the company name. The date "SEP 21 2007" is on the bottom left, and the number "K063798" is on the bottom right.
510(k) SUMMARY
D3 HERPES SIMPLEX VIRUS IDENTIFICATION KIT
| Applicant | DIAGNOSTIC HYBRIDS, INC.350 West State StreetAthens, OHIO 45701 | |||||
|---|---|---|---|---|---|---|
| Contact Information | Gail R. GoodrumVice President, Regulatory and Quality AffairsE-mail: goodrum@dhiusa.comTelephone: 740.593.1784Desk Extension: 740.593.1787FAX: 740.597.1546 | |||||
| Ronald Lollar, Senior Director of Clinical Development -- secondary contact350 W. State StreetAthens, OH 45701740.593.1784 - Phone740.593.0980 - Faxlollar@dhiusa.com | ||||||
| Date of preparation of510(k) summary: | December 18, 2006 | |||||
| Device Name | Trade name - D3 HERPES SIMPLEX VIRUS IDENTIFICATION KITCommon name - Fluorescent antibody test for herpes simplex virusClassification name - ANTISERA, FLUORESCENT, HERPESVIRUS HOMINIS 1,2 (21CFR 866.3305, product code GQL) | |||||
| Legally marketed devicesto which equivalence isclaimed: | K902662 Bartels® Herpes Simplex Virus Fluorescent Monoclonal Antibody Test | |||||
| K904167 Pathodx® Herpes Typing Kit | ||||||
| K880157 MicroTrak® HSV 1/HSV 2 Culture Identification and Typing Test | ||||||
| Device Description | The Diagnostic Hybrids D3 DFA Herpes Simplex Virus Identification Kit includes aDFA Reagent that contains a blend of four fluorescein-labeled murine monoclonalantibodies (MAbs), two directed against HSV type 1 (HSV-1) and two against HSV type2 (HSV-2). The HSV-1 MAbs were developed using HSV-1(f) cell lysate as immunogen-- one has been determined to be directed against HSV-1 glycoprotein C1, the antigento the other is undetermined. The HSV-2 MAbs were developed using a HSV-2recombinant glycoprotein G immunogen. | |||||
| The kit includes the following components:• HSV DFA Reagent - A blend of fluorescein labeled murine monoclonalantibodies directed against antigens produced in HSV-infected cell culture. Thebuffered, stabilized, aqueous solution contains Evan's Blue as a counter-stain and 0.1%sodium azide as preservative.• HSV Antigen Control Slides - Individually packaged control slides containingwells with cell culture derived positive and negative control cells. Each HSV positivewell is identified. The negative wells contain uninfected cells. Each slide is intended tobe stained only one time. |
{1}------------------------------------------------
PBS Concentrate - A 40X concentrate consisting of 4% sodium azide in phosphate buffered saline (after dilution to 1X in water, the concentration of sodium azide in the solution is 0.1%).
Mounting Fluid - an aqueous, buffered, stabilized solution of glycerol and 0.1% sodium azide.
The cells to be tested, on a slide prepared from a tube culture or on a monolayer of cells cultured in a multi-well plate or a coverslip in a shell vial, are fixed in acetone. The HSV DFA Reagent is added to the cells to detect the presence of HSV specific viral antigens. After incubating for 15 to 30 minutes at 35° to 37°C, the stained cells are washed with the supplied Phosphate Buffered Saline (PBS). To prepare the slide for examination, a drop of the supplied Mounting Medium is added to the stained cells and a coverslip is placed on the slide. To prepare the centrifuge enhanced cell cultures for examination, a drop of Mounting Fluid is placed on a clean microscope slide. The coverslip is removed from the shell vial and placed on to the Mounting Fluid.
For multi-well plates, monolayers are fixed with an 80% aqueous acetone solution. The HSV DFA Reagent is added to the cells to detect the presence of any HSV specific viral antigens. After incubating for 15 to 30 minutes at 35° to 37°C, the stained cells are washed with the supplied Phosphate Buffered Saline (PBS). Mounting Fluid is added to each well to cover the monolayers.
The slides or wells are examined using a fluorescence microscope equipped with the correct filter combination for FITC at a magnification of 100-400X. Virus infected cells will be stained with bright apple-green fluorescence while uninfected cells will contain no apple-green fluorescence but will fluoresce red by the Evan's Blue counterstain' which is included in the HSV DFA Reagent.
If no fluorescent cells are found, report result as, "No herpes simplex virus detected". If fluorescent cells are found, report result as, "Herpes simplex virus isolated by cell culture."
Included in the kit are HSV Antigen Control Slides. A Control Slide is intended to function as an indicator that the kit reagents are working properly in the test. [The slides are prepared with wells of HSV infected cells and uninfected cells.] Positive and negative controls must demonstrate appropriate staining characteristics for specimen results to be valid. Controls may also aid in the interpretation of test results.
It is recommended that cell culture positive (infected with known HSV isolate) and negative (uninfected cells) controls be run with each assay to provide a means to ensure adequate performance of the cell culture system used. If control cultures fail to perform correctly, results are considered invalid.
The Diagnostic Hybrids D3 DFA Herpes Simplex Virus Identification Kit is intended for use in the qualitative detection of human herpes simplex virus (HSV) in cell cultures by immunofluorescence using fluoresceinated monoclonal antibodies (MAbs). Negative results do not preclude an infection and should not be used as the sole basis for diagnosis, treatment or other management decisions,
Performance using direct specimen testing has not been evaluated.
Explanation
Intended Use
HSV infections in humans can cause lesions at a variety of sites, e.g., oral-facial, genital, eye, and cutaneous sites.
When an appropriately sensitive cell line is infected with HSV, a characteristic deterioration of cells, termed cytopathic effect (CPE), can be observed. Tube collusions a classic format for virus amplification, can take several days before CPE is evident. In the case of those specimens with low titers of virus, 7 days of culture may be required by the standard tube culture method before CPE can be observed2,3,4,5,6
510(k) summary
Page 5-2 of 5-5
350 West State Street
Athens, Ohio 45701
350 West State Street ▪ ▲thens, Ohio 45701 ▪ ▪ 1-800-344-5847 ▪ ▪ Fax 740-593-0980 ▪ www.chiusa.com
{2}------------------------------------------------
The rate of isolation may be enhanced and the time required for HSV identification may be decreased by centrifugation of specimens in shell vials or multi-well plates containing appropriately sensitive cell lines (centrifuge enhanced technique) 1999
Even so, CPE may be difficult to interpret due to, for instance, deterioration of cells, which can result from toxic components present in the clinical specimen making microscopic examination of the infected cells problematic. Because of this, immunofluorescence confirmation of cell culture is regarded as the standard for confirmation of a HSV positive result.
Fundamental technology and intended use of the device are the same as those of the predicate devices, which are based on a standard immunofluorescence assay technique using cells inoculated with patient specimens. They employ directly labeled fluorescein monoclonal antibodies specific for HSV antigens enabling visualization of the infected cells. A summary is provided in the table below:
| HSV Systems | DFA | DirectSpecimens | CultureConfirmation | FITCLabel | MonoclonalAntibody | DistinguishesHSV-1 and HSV-2 |
|---|---|---|---|---|---|---|
| DiagnosticHybrids | Yes | No | Yes | Yes | Yes | No |
| Bartels®(Trinity) | Yes | No | Yes | Yes | Yes | No |
| PathoDx(Remel) | Yes | Yes | Yes | Yes | Yes | Yes |
| MicroTrak®(Trinity) | Yes | No | Yes | Yes | Yes | Yes |
Non-clinical Performance
Technological
Characteristics
Staining patterns of the conjugated monoclonal antibodies on HSV infected cells were similar to those of the predicate devices.
Analytical specificity was evaluated by staining cultures infected with a number of ATCC reference HSV-1 and HSV-2 strains and found to react with all of them.
The HSV DFA Reagent was tested for cross-reactivity against a wide variety of other microorganisms and cells. No cross-reactivity was observed for 59 virus strains (cultured and processed for staining) or for 17 host culture cell types. Twenty-seven (27) bacterial cultures, one yeast and one protozoan culture were stained and examined for cross-reactivity, including Staphylococcus aureus, a protein-A-producing bacterium. Staining of S. aureus appeared as small points of fluorescence while all other cultures were negative. [Protein A will specifically bind to the Fc portions of conjugated antibodies. Such binding can be distinguished from viral antigen binding on the basis of morphology, i.e., S. aureus-bound fluorescence appears as small (~1 micron diameter), bright dots.] [Note: Results from cell cultures with bacterial contamination must, therefore, be interpreted with caution.]
Stringent conditions for cross-reactivity testing were achieved by using a high concentration of the HSV DFA Reagent and high titers of microorganisms. The DFA Reagent was prepared at 1.5X the concentration that is provided in the kit.
Depending on the particular virus, 500 to 715 TCIDso viruses were inoculated into shell vial or multi-well plate cultures and incubated for 24 to 48 hours to yield a 1+ to 3+ infection, processed and stained with the 1.5X DFAs according to the procedure detailed in the product insert. Stained cells were examined at 200x magnification. Cell cultures were stained as confluent monolayers,
Bacteria and yeast were cultured, processed as suspensions, then spotted on microscope slides (at CFUs ranging from 6.4x104 to 2.93x107/well in a 10 µL dot, depending on the bacterium), then stained with the 1.5X DFAs according to the procedure in the product insert. Stained slides were examined at 400X magnification.
510(k) summary
Page 5-3 of 5-5
350 West State Street • Athens, Ohio 45701 • 1-800-344-5847 • Fax 740-593-0980 • www.dhiusa.com
Athens, Ohio 45701 •
- 1-800-344-5847 -
{3}------------------------------------------------
| Virus Strains Tested for Cross Reactivity with D³ HSV DFA Reagent | |||||
|---|---|---|---|---|---|
| Organism | Strain or Type | Inoculum(TCID₅₀) | Organism | Strain or Type | Inoculum(TCID₅₀) |
| Adenovirus | Type 1 | 715 | Influenza B | Hong Kong | 715 |
| Adenovirus | Type 3 | 715 | Influenza B | Maryland | 715 |
| Adenovirus | Type 5 | 715 | Influenza B | Mass | 715 |
| Adenovirus | Type 6 | 715 | Influenza B | Taiwan | 715 |
| Adenovirus | Type 7 | 715 | Influenza B | GL | 715 |
| Adenovirus | Type 8 | 715 | Influenza B | JH-001 isolate | 715 |
| Adenovirus | Type 10 | 715 | Influenza B | Russia | 715 |
| Adenovirus | Type 13 | 715 | RSV | Long | 715 |
| Adenovirus | Type 14 | 715 | RSV | Wash | 715 |
| Adenovirus | Type 18 | 715 | RSV | 9320 | 715 |
| Adenovirus | Type 31 | 715 | Parainfluenza 1 | C-35 | 715 |
| Adenovirus | Type 40 | 715 | Parainfluenza 2 | Greer | 715 |
| Adenovirus | Type 41 | 715 | Parainfluenza 3 | C 243 | 715 |
| Influenza A | Aichi | 715 | Parainfluenza 4a | M-25 | 715 |
| Influenza A | Mal | 715 | Parainfluenza 4b | CH19503 | 715 |
| Influenza A | Hong Kong | 715 | CMV | Towne | 700 |
| Influenza A | Denver | 715 | CMV | Davis | 700 |
| Influenza A | Port Chalmers | 715 | CMV | AD169 | 700 |
| Influenza A | Victoria | 715 | VZV | Webster | 500 |
| Influenza A | New Jersey | 715 | VZV | Allen | 500 |
| Influenza A | PR | 715 | Epstein-Barr | Commercially available slides stained.¹ | |
| Influenza A | WS | 715 | Rubeola | ||
| Mumps | |||||
| Echovirus | Types 4, 6, 9,11, 30, 34 | Commercially available slides stained.¹ | HPV | Types 6, 11 | Commercially available slides stained.¹ |
| Coxsackievirus | Types B1, B2,B3, B4, B5, B6 | Commercially available slides stained.¹ | |||
| Cell Lines Tested for Cross Reactivity with D³ HSV DFA Reagent | |||||
| A-549 | MRHF | RhMK II | |||
| BGMK | Mv1Lu | pRK | |||
| HEp-2 | NCI-H292 | RD | |||
| LLC-MK2 | pCMK | R-Mix | |||
| MDCK | pRhMK | Vero | |||
| MRC-5 | WI-38 | ||||
| Microorganisms Tested for Cross Reactivity with D³ HSV DFA Reagent | |||||
| BACTERIA | CFUTESTED | BACTERIA | CFUTESTED | ||
| Acinetobacter calcoaceticus | 9.7 x 10⁵ | Salmonella typhimurium | 1.7 x 10⁶ | ||
| Bordetella bronchiseptica | 1.7 x 10⁵ | Staphylococcus aureus | 1.0 x 10⁷ | ||
| Bordetella pertussis | 4.6 x 10⁶ | Streptococcus agalactiae | 9.6 x 10⁶ | ||
| Corynebacterium diphtheriae | 2.5 x 10⁶ | Streptococcus pneumoniae | 8.0 x 10⁵ | ||
| Escherichia coli | 2.6 x 10⁵ | Streptococcus pyogenes | 2.9 x 10⁷ | ||
| Gardnerella vaginalis | 5.0 x 10⁵ | Acholeplasma laidlawi | ~6 x 10⁴ | ||
| Haemophilis influenzae type A | 9.3 x 10⁵ | Mycoplasma hominis | ~6 x 10⁴ | ||
| Klebsiella pneumoniae | 6.4 x 10⁶ | Mycoplasma orale | ~6 x 10⁴ | ||
| Legionella pneumophila | 6.5 x 10⁴ | Mycoplasma pneumoniae | ~6 x 10⁴ | ||
| Moraxella cartarrhalis | 6.4 x 10⁴ | Mycoplasma salivarium | ~6 x 10⁴ | ||
| Neisseria gonorrhoeae | 1.3 x 10⁶ | Ureaplasma uralyticum | ~6 x 10⁴ | ||
| Proteus mirabilis | 2.1 x 10⁶ | Chlamydophila pneumoniae | Commercially available slides stained.¹ | ||
| Pseudomonas aeruginosa | 1.0 x 10⁷ | Chlamydia trachomatis | |||
| Salmonella enteriditis | 2.5 x 10⁶ |
Some microorganisms were procured from an external source as prepared microscope slides, intended to be used as positive controls for assays.
350 West State Street ▪ ▲thens, Ohio 45701 ▪ ▪ 1-800-344-5847 ▪ ▪Fax 740-593-0980 ▪ www.dhiusa.com
a Test material is from commercially available prepared slides. Each positive well contained 10% to 50% reactive cells.
{4}------------------------------------------------
| YEAST | PROTOZOAN | |
|---|---|---|
| Candida glabrata | Trichomonas vaginalis | [Commercially available slides stained.]1 |
| $8.7 \times 10^6$ |
Clinical Performance
Clinical studies have been conducted at four different laboratories where they compared the D3 DFA HSV Kit performance to that of comparison tests using five hundred and thirty (530) specimens. A combination of fresh (250) and frozen (280) specimens were tested. Three specimens from site 4 were not evaluated due to bacterial contamination of the monolayers, leaving 527 for analysis.
Two study sites used tube cultures, one used shell vial culture, and one used multi-well plates. Specimens were processed and cultured according to each laboratory's established procedures and testing performed according to the respective tests' instructions for use. The resulting stained cells were microscopically evaluated and results reported as positive or negative for identification of HSV.
Positive and Negative Percent Agreement between the Subject and Comparison test results were calculated and reported at 95% confidence interval.
| Table of Combined Specimen Results from Four Study Sites | |||
|---|---|---|---|
| Comparison Device | |||
| + | - | ||
| Subject DeviceDiagnosticHybrids | + | 200 | 1 |
| - | 1 | 325 | |
| Positive Percent Agreementb (PPA) | 99.5% | ||
| 95% CIc – PPA | 97.3% - 100% | ||
| Negative Percent Agreementd (NPA) | 99.7% | ||
| 95% CI – NPA | 98.3% - 100% |
Specter, S., Hodinka, R. L., and Young, S.A. 2000, Clinical Virology Manual, Washington D.C., ASM Press, 420-424. 2 Bryson, Y.J., M. Dillon, M. Lovett, G. Acura, S. Taylor, J.D. Cherry, L. Johnson, E. Weismeier, W. Growdeon, T.
Creagh-Kirk and R. Keeney, 1983. "Treatment of first episodes of genital Herpes simplex virus infection with oral acyclovir: A randomized double-blind controlled trial in normal subjects". New Eng. J. Med., 308: 916-921.
8 Reeves, E.O., L. Corey, H.G. Adams. L.A. Vontver and K.K. Holmes. 1981. "Risk of recurrence after first episodes of genital herpes: relation to HSV type and antibody response". New Eng. J. Med., 305: 315-319.
for Viral, Rickettsial and Chiamydial Infections. Sixth Edition, N.J. Schmidt and R.W. Emmons, (eds), American Public Health Association, Inc., Washington, D.C.
് Gleaves, C.A., D.J. Wilson, A.D. Wolf and T.F. Smith. 1985. "Detection and Serotyping of Herpes simplex Virus in in MRC-5 cells by use of centrifugation and monoclonal antibodies 16h post-incculation" . J. Clin. Micro., 21: 29-32.
8 Moore, D.F. 1984. "Comparison of human fibroblast cells and primary rabbit kidney cells for isolation of Herpes and simplex virus". J. Clin. Micro. 19: 548-549.
510(k) summary
Page 5-5 of 5-5
350 West State Street • Athens, Ohio 45701 • 1-800-344-5847 • Fax 740-593-0980 • www.dhiusa.com
3 Dulbecco, R. and H.S. Ginsberg. 1973. "Herpesviruses", Chapter 55 in Microbiology, Third Edition, D.D. D. D. D. D. D. D. D. D. D. D. D. D. D. D. D. S. et al. (eds.), Harper and Row, Hagerstown.
Gleaves, C.A., D.J. Wilson, A.D. Wold and T.F. Smith. 1985. "Detection and Serotyping of Herpes simplex Virus in MRC-5 cells by use of centrifugation and monoclonal antibodies 16h post-inoculation". J. Clin. Micro, 21: 29-32.
for Viral, Rickettsial and Chlamydial Infections, Sixth Edition, N.J. Schmidt and R.W. Emmons, (eds), American Public Health Association, Inc., Washington, D.C.
" Positive Percent Agreement", or "PPA", values were caculated according to {[Total Number of Positive Results in Agreement by both Subject and Predicate Tests) divided by ((Total Number of Positive Results in Agreement by both Subject and Predicate Tests) plus (Number of Results Positive by Predicate but Negative by Subject)]} multiplied by 100%.
f 95% Cl" refers to 95% Confidence Intervals, which were calculated according to Exact method (Clopper, C. and S. Pearson, Biometrika 26:404-413, 1934).
d "Negative Percent Agreement", or "NPA", values were calculated according to {[Total Number of Negative Results in Agreement by both Subject and Predicate Tests) divided by [(Total Number of Negative Results in Agreement by both Subject and Predicate Tests) plus (Number of Results Negative by Results in Rositive by Subject)]) multiplied by 100%.
{5}------------------------------------------------
Image /page/5/Picture/1 description: The image shows a circular logo for the U.S. Department of Health & Human Services. The logo features the department's emblem, which is a stylized depiction of an eagle or bird-like figure. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" are arranged around the emblem in a circular fashion.
SEP 2 1 2007
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Ms. Gail R. Goodrum Vice President, Regulatory and Quality Affairs Diagnostic Hybrids, Inc. 350 West State Street Athens, OH 45701
Re: K063798
Trade/Device Name: Diagnostic Hybrids DJ DFA Herpes Simplex Virus Identification Kit Regulation Number: 21 CFR § 866.3350 Regulation Name: Herpes simplex virus serological reagents Regulatory Class: II Product Code: GQN Dated: August 10, 2007 Received: August 13, 2007
Dear Ms. Goodrum:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
{6}------------------------------------------------
Page 2 -
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to 10(a)/ marketed predicate device results in a classification for your device and thus, permitts your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at 240-276-0450. 1500. please note the regulation entitled, "Misbranding by reference to premarket notification". (211CR Part 807.97). For questions regarding postmarket surveillance, please contact Chorners (Cross of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-376-307 questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Sally attaym
Sally A. Hojvat, M.Sc., Ph.D. Director Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
{7}------------------------------------------------
Indications for Use
510(k) Number (if known): K063798
Device Name: Diagnostic Hybrids D3 DFA Herpes Simplex Virus Identification Kit
Indications for Use: The Diagnostic Hybrids D3 DFA Herpes Simplex Virus Identification Kit is intended for use in the qualitative detection of human herpes simplex virus (HSV) in cell cultures by immunofluorescence using fluoresceinated monoclonal antibodies (MAbs), Negative results do not preclude an infection and should not be used as the sole basis for diagnosis, treatment or other management decisions.
Performance using direct specimen testing has not been evaluated.
Prescription Use X (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
Ue Sch
Division Sign-Off
Office of In Vitro Diagnostic Device Evaluation and Safety
510(k) K063778
§ 866.3305 Herpes simplex virus serological assays.
(a)
Identification. Herpes simplex virus serological assays are devices that consist of antigens and antisera used in various serological tests to identify antibodies to herpes simplex virus in serum. Additionally, some of the assays consist of herpes simplex virus antisera conjugated with a fluorescent dye (immunofluorescent assays) used to identify herpes simplex virus directly from clinical specimens or tissue culture isolates derived from clinical specimens. The identification aids in the diagnosis of diseases caused by herpes simplex viruses and provides epidemiological information on these diseases. Herpes simplex viral infections range from common and mild lesions of the skin and mucous membranes to a severe form of encephalitis (inflammation of the brain). Neonatal herpes virus infections range from a mild infection to a severe generalized disease with a fatal outcome.(b)
Classification. Class II (special controls). The device is classified as class II (special controls). The special control for the device is FDA's revised guidance document entitled “Class II Special Controls Guidance Document: Herpes Simplex Virus Types 1 and 2 Serological Assays.” For availability of the guidance revised document, see § 866.1(e).